US nonclinical test design guidance:
This article was originally published in Clinica
The US FDA has issued a draft guidance on how to design nonclinical tests to determine the potential risk of radiation-induced injuries months or even years after a patient undergoes radiation therapy for cancer or other conditions. The guidance is not intended for diagnostic radiopharmaceuticals or for radiobiologicals, a June 20 Federal Register notice pointed out. Comments are due by September 19.
You may also be interested in...
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.
Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.